Catalyst Pharmaceuticals, Inc.

352 articles about Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceutical Partners: Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting

  6/9/2010

• Catalyst Pharmaceutical Partners Announces First Quarter 2010 Financial Results

  5/18/2010

• Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference

  5/7/2010

• Catalyst Pharmaceutical Partners Regains Compliance with The Nasdaq Stock Market -- New York Minimum Bid Price Rule

  4/26/2010

• Catalyst Pharmaceutical Partners Signs Definitive Agreement With the National Institute on Drug Abuse (NIDA) To Conduct U.S. Phase II(B) Clinical Trial for Cocaine Addiction

  4/13/2010

• Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2009 Financial Results

  4/1/2010

• Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference

  3/10/2010

• Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference

  2/25/2010

• Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction

  2/23/2010

• Catalyst Pharmaceutical Partners And The National Institute on Drug Abuse (NIDA) Plan To Initiate U.S. Phase II(B) Clinical Trial For Cocaine Addiction

  2/23/2010

• Catalyst Pharmaceutical Partners to Discuss Development Plans for CPP-115 on February 23, 2010 Conference Call

  2/22/2010

• Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies

  2/17/2010

• Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results

  11/13/2009

• Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results

  11/12/2009

• Catalyst Pharmaceutical Partners Announces Extension of Chief Executive's Employment Agreement

  10/13/2009

• Catalyst Pharmaceutical Partners Announces the Closing of $3.97 Million Registered Direct Offering

  10/7/2009

• Catalyst Pharmaceutical Partners Plans $4 Million Offering

  10/2/2009

• Catalyst Pharmaceutical Partners to Continue Development of Addiction Drug

  10/1/2009

• Catalyst Pharmaceutical Partners to Transfer To NASDAQ Capital Market

  9/3/2009

• Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University

  8/31/2009